Found 82 with Last Name = 'fraley' and Initial = 'a' TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 0.800nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 0.800nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.10nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.20nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.30nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.30nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.40nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.60nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.90nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 1.90nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 2.20nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 2.20nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 2.40nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 2.70nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 2.90nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of cIAP1 BIR2-3 (154 to 352 residues) (unknown origin) fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 3.20nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 4.40nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 4.90nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of cIAP1 BIR2-3 (154 to 352 residues) (unknown origin) fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 5.20nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 5.70nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 6.5nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of cIAP1 BIR2-3 (154 to 352 residues) (unknown origin) fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 8nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 8.60nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of XIAP BIR2-3 (125 to 356 residues) C202A/C213G mutant (unknown origin) fluoresceinated dimeric SMAC peptide based fluorescence polarizat...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 9.10nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 10.1nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 10.3nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 11nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 12.8nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 13.9nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 14.6nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 16.5nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 16.9nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR2-3 (125-356, C...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 22nMAssay Description:Inhibition of XIAP BIR2-3 (125 to 356 residues) C202A/C213G mutant (unknown origin) fluoresceinated dimeric SMAC peptide based fluorescence polarizat...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Inhibition of XIAP BIR2-3 (125 to 356 residues) C202A/C213G mutant (unknown origin) fluoresceinated dimeric SMAC peptide based fluorescence polarizat...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Inhibition of cIAP1 BIR3 (154 to 352 residues) (unknown origin) by fluoresceinated dimeric SMAC peptide based fluorescence polarization assayMore data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3(Homo sapiens (Human))
Ensemble Therapeutics
Curated by ChEMBL
Ensemble Therapeutics
Curated by ChEMBL
Affinity DataIC50: 29nMAssay Description:Inhibition of XIAP BIR3 (241 to 356 residues) (unknown origin) incubated for 60 mins by fluoresceinated modified SMAC peptide based fluorescence pola...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 3/E3 ubiquitin-protein ligase XIAP(Homo sapiens (Human))
Ensemble Therapeutics
US Patent
Ensemble Therapeutics
US Patent
Affinity DataIC50: 29nMAssay Description:Assays were performed in black, flat-bottom, 384-well plates. The final assay volume was 50 μL prepared from additions of His-BIR3 (241-356, XIA...More data for this Ligand-Target Pair
